ARA-290¶

Identification¶

Property	Value
CAS Number	1208243-50-8
Molecular Formula	C₅₁H₈₄N₁₆O₁₉
Molecular Weight	~1,258.4 Da
Sequence	H-Gln-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH
Amino Acid Count	11
Appearance	White to off-white lyophilized powder
Purity Standard	≥99% by HPLC
Solubility	Soluble in sterile water or PBS
Storage	2–8°C, desiccated, protect from light

Category: Healing & Recovery

Catalog SKU: PSH-ARA290-5MG

Research Background¶

ARA-290 is an 11-amino acid peptide engineered from the helix B domain of erythropoietin (EPO). The key innovation behind ARA-290 is its receptor selectivity: it activates the Innate Repair Receptor (IRR, also known as the β-common receptor/CD131 heterodimer) but does not bind the classical EPO receptor (EPO-R). This receptor discrimination separates tissue-protective signaling from erythropoietic signaling — in research models, ARA-290 demonstrates tissue protection and anti-inflammatory effects without elevating hematocrit.

Key Mechanisms¶

Mechanism	Details
IRR Agonism	Selective Innate Repair Receptor (CD131/β-common receptor) activation → no EPO-R binding
JAK2/STAT3 Pathway	Anti-inflammatory signaling cascade → suppression of pro-inflammatory cytokines
Anti-Apoptotic	Bcl-2 upregulation; caspase-3 inhibition; mitochondrial membrane stabilization
No Erythropoiesis	Engineered to avoid EPO-R homodimer → no hematocrit elevation or thrombosis risk

Research Focus Areas¶

Small Fiber Neuropathy¶

Nerve fiber density preservation; pain threshold normalization

Cardiac Ischemia-Reperfusion¶

Infarct size reduction; caspase-3 suppression

Wound Healing¶

Chronic wound models; diabetic ulcer re-epithelialization

Renal Protection¶

Acute kidney injury models; tubular cell survival

Neuroinflammation¶

Microglial activation modulation; IL-1β/TNF-α suppression

Available Configurations¶

Configuration	Content	Best For
Standard Kit	5 mg × 10 vials	Tissue protection models; evaluation
Bulk Kit	10 mg × 10 vials	Chronic neuropathy models; repeat orders
Custom	Custom mg × custom vials	OEM; private-label; protocol-specific

Tiered Wholesale Pricing¶

Volume	Discount	For
1 kit	List price	Evaluation; competitive analysis
5+ kits	10% off	Initial portfolio expansion
20+ kits	20% off	Mid-size distributors
50+ kits	30% off	Regional distributors

Quality Specifications¶

Parameter	Method	Criterion
Purity	HPLC at 214 nm, C18 column	≥99.0% peak area
Identity (MW)	ESI-MS	~1,258.4 ± 1.0 Da
Appearance	Visual inspection	White to off-white powder
Peptide Content	Amino acid analysis	≥80% net peptide
Residual Moisture	Karl Fischer	≤3%

Frequently Asked Questions¶

Q1: What is ARA-290 and how does it differ from EPO?¶

ARA-290 is an 11-amino acid peptide derived from the helix B domain of erythropoietin. It selectively activates the Innate Repair Receptor (IRR/CD131) without binding the classical EPO receptor — providing tissue protection without erythropoiesis (no increase in hematocrit). This receptor selectivity is the defining feature.

Q2: What research applications is ARA-290 used for?¶

Primarily neuroprotection (small fiber neuropathy, peripheral nerve injury models), cardiac ischemia-reperfusion injury reduction, wound healing (chronic and diabetic ulcer models), renal protection, and neuroinflammation research.

Q3: Why doesn't ARA-290 affect red blood cell production?¶

EPO's tissue-protective and erythropoietic activities are mediated by distinct receptor complexes. ARA-290 was specifically engineered to only activate the IRR/CD131 heterodimer (tissue protection) and not the EPO-R homodimer (erythropoiesis).

Q4: How should ARA-290 be stored?¶

Lyophilized powder: 2–8°C, desiccated, 24-month stability. After reconstitution in sterile water or PBS, aliquot single-use portions and store at -20°C. Avoid freeze-thaw cycles.

Q5: What documentation is included with ARA-290?¶

Batch-specific COA (HPLC purity, ESI-MS identity confirmation), commercial invoice, and packing list. Full chromatogram and MS spectrum available on request.

Key Research References¶

Reference	PMID	Key Finding
Brines M et al. "ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathy in subjects with type 2 diabetes." Mol Med. 2015;21(1):720–730.	25387363	ARA-290 improved small fiber neuropathy symptoms and metabolic control in T2D without elevating hematocrit; confirmed IRR selectivity
Dahan A et al. "ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study." Anesthesiology. 2014;120(5):1231–1243.	24529189	ARA-290 demonstrated analgesic effects in neuropathic pain models via IRR/CD131 receptor with no hematopoietic effects

Stability & Storage¶

Condition	Degradation Profile
Lyophilized Storage	Standard peptide stability; 24 months at 2–8°C in desiccated environment, protect from light
Neutral pH (6.0–7.5)	Stable; recommended for reconstitution in sterile water or PBS
Alkaline pH (>8.0)	Risk of deamidation at Asn¹⁰ and Gln residues; avoid alkaline buffers for extended storage
Reconstituted Solution	24 h at 2–8°C; aliquot single-use portions and freeze at −20°C. Avoid freeze-thaw cycles
Temperature	No special handling beyond standard lyophilized peptide storage

Source & Purchase¶

For research-grade ARA 290 and related compounds in this category, visit the PeptideSourceHub category page for bulk pricing and available specifications.

Browse ARA 290 & Related Products →

Product	Link
BPC-157	bpc-157.md — Protection compound for tissue repair
Thymosin Beta-4 (Full Length)	thymosin-beta-4.md — Full 43-aa tissue regeneration peptide
TB-500	tb-500.md — Actin-binding domain fragment
GHK-Cu	ghk-cu.md — Copper tripeptide for wound healing